

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
204307Orig1s000

LABELING

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VITUZ safely and effectively. See full prescribing information for VITUZ.

VITUZ (hydrocodone bitartrate and chlorpheniramine maleate) oral solution, CIII
Initial U.S. Approval: 1987

INDICATIONS AND USAGE

Vituz® Oral Solution is a combination of hydrocodone bitartrate, an antitussive, and chlorpheniramine maleate, a histamine-1 (H1) receptor antagonist, indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold (1 1)

Limitations of Use:

Not indicated for pediatric patients under 18 years of age (1 1)

DOSAGE AND ADMINISTRATION

- For Oral Use Only (2)
- Adults 18 years of age and older: 5 mL every 4 to 6 hours as needed, not to exceed 4 doses (20 mL) in 24 hours (2)

DOSAGE FORMS AND STRENGTHS

Each 5 mL of Vituz Oral Solution contains: hydrocodone bitartrate, USP, 5 mg and chlorpheniramine maleate, USP, 4 mg (3)

CONTRAINDICATIONS

- Patients with known hypersensitivity to hydrocodone bitartrate, chlorpheniramine, or any of the inactive ingredients of Vituz (4)
- Patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy (4)
- Patients with narrow angle glaucoma, urinary retention, severe hypertension or severe coronary artery disease (4)

WARNINGS AND PRECAUTIONS

- Dose-related respiratory depression: Use with caution (5 1)
- Drug Dependence: Prescribe with caution that is appropriate to the use of other opioids (5 2)

- Head injury and increased intracranial pressure: Avoid in patients with head injury, intra-cranial lesions, or increased intracranial pressure (5 3)
- Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery (5 4)
- Avoid concurrent use of alcohol or other central nervous system depressants (5 4)
- Acute abdominal conditions: Use with caution in patients with acute abdominal conditions (5 5)
- Coexisting Conditions: Use with caution in patients with thyroid disease, Addison's disease, prostatic hypertrophy or urethral stricture, or asthma (5 9)

ADVERSE REACTIONS

Most common adverse reactions were sedation, somnolence, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, nausea, psychic dependence, mood changes; blurred, double, or other visual disturbances; confusion, headache, euphoria, facial dyskinesia, feeling faint, lightheadedness, agitation, irritability, tremor (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hawthorn Pharmaceuticals, Inc. at 1-800-856-4393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants: Avoid use with Vituz; may cause additive CNS depression (7 1)
- MAOIs or tricyclic antidepressants: Do not use. May increase the effect of either the antidepressant or hydrocodone (7 2)
- Anticholinergic drugs: Use with caution. Additive adverse effects resulting from cholinergic blockade (e.g., xerostomia, blurred vision, or constipation) may occur (7 3)

USE IN SPECIFIC POPULATIONS

- Renal Impairment: Use with caution (8 6)
- Hepatic Impairment: Use with caution (8 7)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 02/2013

Deleted: The m

Deleted: of Vituz Oral Solution include:

Deleted: S

Deleted:

Deleted:

Deleted: M

Deleted:

Deleted: ¶

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
1 1 Cough and Upper Respiratory Allergy Symptoms

2 DOSAGE AND ADMINISTRATION
2 1 Adults 18 Years of Age and Older

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS
5 1 Respiratory Depression
5 2 Drug Dependence
5 3 Head Injury and Increased Intracranial Pressure
5 4 Activities Requiring Mental Alertness
5 5 Acute Abdominal Conditions
5 6 Co-administration with Anticholinergics
5 7 Co-administration with MAOIs or Tricyclic Antidepressants
5 8 Dosing
5 9 Coexisting Conditions
5 10 Renal Impairment
5 11 Hepatic Impairment

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS
7 1 Opioids, Antihistamines, Antipsychotics, Anti-anxiety Agents, or Other CNS Depressants (Including Alcohol)
7 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants
7 3 Anticholinergic Drugs

8 USE IN SPECIFIC POPULATIONS
8 1 Pregnancy
8 2 Labor and Delivery

8 3 Nursing Mothers
8 4 Pediatric Use
8 5 Geriatric Use
8 6 Renal Impairment
8 7 Hepatic Impairment

9 DRUG ABUSE AND DEPENDENCE
9 1 Controlled Substance
9 2 Abuse
9 3 Dependence

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12 1 Mechanism of Action
12 3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13 1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION
17 1 Overdosage
17 2 Dosing
17 3 Concomitant Use of Alcohol and Other Central Nervous System Depressants
17 4 Activities Requiring Mental Alertness
17 5 Drug Dependence
17 6 MAOIs

*Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Cough and Upper Respiratory Allergy Symptoms

Vituz[®] Oral Solution is indicated for relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older.

Important Limitations of Use

Not indicated for pediatric patients under 18 years of age [*see Use in Specific Populations (8.4)*].

2 DOSAGE AND ADMINISTRATION

Administer Vituz Oral Solution by the oral route only. Measure Vituz Oral Solution with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose [*see Warnings and Precautions (5.8)*].

2.1 Adults 18 Years of Age and Older

5 mL every 4 to 6 hours as needed, not to exceed 4 doses (20 mL) in 24 hours.

3 DOSAGE FORMS AND STRENGTHS

Vituz is a clear, colorless to light yellow, grape-flavored liquid.

5 mL of Vituz Oral Solution contains: hydrocodone bitartrate, USP, 5 mg and chlorpheniramine maleate, USP, 4 mg [*see Description (11)*].

4 CONTRAINDICATIONS

Vituz Oral Solution is contraindicated in:

- Patients with known hypersensitivity to hydrocodone bitartrate, chlorpheniramine maleate or any of the inactive ingredients of Vituz Oral Solution.
- Patients receiving MAOI therapy or within 14 days of stopping such therapy.
- Patients with narrow angle glaucoma, urinary retention, severe hypertension, or severe coronary artery disease.

5 WARNINGS AND PRECAUTIONS

5.1 Respiratory Depression

Hydrocodone bitartrate, one of the active ingredients in Vituz Oral Solution, produces dose-related respiratory depression by directly acting on brain stem respiratory centers. Overdose of hydrocodone bitartrate in adults has been associated with fatal respiratory depression, and the use of hydrocodone bitartrate in children less than 6 years of age has been associated with fatal respiratory depression. Exercise caution when administering Vituz Oral Solution because of the potential for respiratory

depression. If respiratory depression occurs, discontinue Vituz Oral Solution and use naloxone hydrochloride when indicated to antagonize the effect and other supportive measures as necessary [see *Overdosage (10)*].

5.2 Drug Dependence

Hydrocodone can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Vituz Oral Solution. Prescribe and administer Vituz with the same degree of caution appropriate to the use of other opioid drugs [see *Drug Abuse and Dependence (9.2, 9.3)*].

5.3 Head Injury and Increased Intracranial Pressure

The respiratory depression effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of Vituz Oral Solution should be avoided in these patients.

5.4 Activities Requiring Mental Alertness

Hydrocodone bitartrate and chlorpheniramine maleate, the active ingredients in Vituz Oral Solution, may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Vituz Oral Solution. Concurrent use of Vituz Oral Solution with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.

5.5 Acute Abdominal Conditions

Vituz Oral Solution should be used with caution in patients with acute abdominal conditions since the administration of hydrocodone may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus [see *Drug Interactions (7.3)*].

5.6 Co-administration with Anticholinergics

The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus. Exercise caution when using Vituz Oral Solution in patients taking anticholinergic medications [see *Drug Interactions (7.3)*].

5.7 Co-administration with MAOIs or Tricyclic Antidepressants

Vituz Oral Solution should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with hydrocodone bitartrate,

one of the active ingredients in Vituz Oral Solution, may increase the effect of either the antidepressant or hydrocodone [see *Contraindications (4) and Drug Interactions (7.2)*].

5.8 Dosing

Patients should be advised to measure Vituz Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions [see *Overdosage (10)*]. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose.

5.9 Coexisting Conditions

Vituz Oral Solution should be used with caution in patients with thyroid disease, Addison's disease, prostatic hypertrophy, urethral stricture, or asthma.

5.10 Renal Impairment

Vituz Oral Solution should be used with caution in patients with severe renal impairment [see *Use in Specific Populations (8.6)*].

5.11 Hepatic Impairment

Vituz Oral Solution should be used with caution in patients with severe hepatic impairment [see *Use in Specific Populations (8.7)*].

6 ADVERSE REACTIONS

Use of hydrocodone bitartrate, a semisynthetic opioid, may result in the following:

- Respiratory depression [see *Warnings and Precautions (5.1) and Overdosage (10)*]
- Drug dependence [see *Warnings and Precautions (5.2)*]
- Increased intracranial pressure [see *Warnings and Precautions (5.3) and Overdosage (10)*]
- Decreased mental alertness with impaired mental and/or physical abilities [see *Warnings and Precautions (5.4)*]
- Paralytic ileus [see *Warnings and Precautions (5.5)*]

Use of chlorpheniramine, an antihistamine, may result in:

- Decreased mental alertness with impaired mental and/or physical abilities [see *Warnings and Precautions (5.4)*]

The following adverse reactions have been identified either during clinical trials of hydrocodone bitartrate and/or chlorpheniramine maleate or during their use post-approval. Because these reactions may be reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The most common adverse reactions of Vituz Oral Solution include: Sedation, somnolence, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, nausea, psychic dependence, mood changes; blurred, double, or other visual disturbances; confusion, headache, euphoria, facial dyskinesia, feeling faint, lightheadedness, agitation, irritability, tremor.

Other adverse reactions include:

Respiratory: Dryness of the pharynx and respiratory passages, occasional tightness of the chest, laryngismus, wheezing, or troubled breathing.

Gastrointestinal System: Nausea and vomiting (more frequent in ambulatory than in recumbent patients), constipation, abdominal distension, abdominal pain, acute pancreatitis, dry mouth, dyspepsia, epigastric distress, and/or loss of appetite.

Genitourinary System: Ureteral spasm, spasm of vesicle sphincters, urinary retention, dysuria, urinary frequency, urinary hesitancy.

Dermatological System: Skin rash, pruritus, erythema, urticaria, excessive perspiration.

7 DRUG INTERACTIONS

No specific interaction studies have been conducted with Vituz Oral Solution.

7.1 Opioids, Antihistamines, Antipsychotics, Anti-anxiety Agents, or Other CNS Depressants (Including Alcohol)

The use of opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants concomitantly with Vituz Oral Solution may cause an additive CNS depressant effect and should be avoided.

7.2 MAOIs and Tricyclic Antidepressants

Do not prescribe Vituz Oral Solution if the patient is taking a prescription MAOI (i.e., certain drugs used for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone [*see Warnings and Precautions (5.7)*].

7.3 Anticholinergic Drugs

Hydrocodone and chlorpheniramine should be administered cautiously to persons receiving other anticholinergic drugs in order to avoid paralytic ileus and excessive anticholinergic effects.

Additive adverse effects resulting from cholinergic blockade (e.g., xerostomia, blurred vision, or constipation) may occur when anticholinergic drugs are administered with chlorpheniramine [*see Warnings and Precautions (5.6)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category C

There are no adequate and well-controlled studies of Vituz Oral Solution in pregnant women. Reproductive toxicity studies have not been conducted with Vituz Oral Solution; however, studies are available with individual active ingredients or related active ingredients. Hydrocodone was teratogenic in hamsters. Codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats. A single retrospective study reported that chlorpheniramine was teratogenic in humans; however, the significance of these findings was not known. Developmental toxicity was also evident with chlorpheniramine in mice and rats. Because animal reproduction studies are not always predictive of human response, Vituz Oral Solution should be used during pregnancy only if the benefit justifies the potential risk to the fetus.

Hydrocodone:

Hydrocodone has been shown to be teratogenic in hamsters when given in a dose approximately 35 times the maximum recommended human daily dose (MRHDD) (on a mg/m² basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 50 times the MRHDD of hydrocodone (on a mg/m² basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 25 and 120 times, respectively, the MRHDD of hydrocodone (on a mg/m² basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.

Chlorpheniramine:

A retrospective study found a small, but statistically significant, association between maternal use of chlorpheniramine and inguinal hernia and eye or ear anomalies in children. Other retrospective studies have found that the frequency of congenital anomalies, in general, was not increased among offspring of women who took chlorpheniramine during pregnancy. The significance of these findings to the therapeutic use of chlorpheniramine in human pregnancy is not known.

In studies with chlorpheniramine in which pregnant rats and rabbits were dosed throughout organogenesis, oral doses up to approximately 20 and 25 times the MRHDD on a mg/m² basis, respectively, produced no adverse developmental effects. However, when mice were dosed throughout pregnancy, a dose approximately 5 times the MRHDD (on a mg/m² basis at an oral dose of 20 mg/kg/day) was embryolethal, and postnatal survival was decreased when dosing was continued after parturition. Embryolethality was also observed when male and female rats were dosed with approximately 5 times the MRHDD (on a mg/m² basis at an oral dose of 10 mg/kg/day) prior to mating.

Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.

8.2 Labor and Delivery

As with all opioids, administration of Vituz Oral Solution to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.

8.3 Nursing Mothers

Caution should be exercised when Vituz is administered to nursing mothers. Hydrocodone and chlorpheniramine are excreted in human milk. The clinical significance is unknown; however, the anticholinergic action of chlorpheniramine may suppress lactation if taken prior to nursing. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Vituz Oral Solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of Vituz Oral Solution in pediatric patients under 18 years of age have not been established. The use of hydrocodone in children less than 6 years of age has been associated with fatal respiratory depression [*see Warnings and Precautions (5.1)*].

8.5 Geriatric Use

Clinical studies have not been conducted with Vituz Oral Solution. Other reported clinical experience with the individual active ingredients of Vituz Oral Solution has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6 Renal Impairment

Vituz Oral Solution should be given with caution in patients with severe impairment of renal function.

8.7 Hepatic Impairment

Vituz Oral Solution should be given with caution in patients with severe impairment of hepatic function.

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Vituz Oral Solution is a Schedule III controlled prescription containing hydrocodone bitartrate and should be prescribed and administered with caution.

9.2 Abuse

Hydrocodone can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Vituz Oral Solution, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.

9.3 Dependence

Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, Vituz Oral Solution should be prescribed and administered with caution.

Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy.

10 OVERDOSAGE

No human overdosage data are available for Vituz Oral Solution.

Hydrocodone:

Overdosage with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest, and death may occur.

Chlorpheniramine:

Manifestations of chlorpheniramine overdosage may vary from central nervous system depression to stimulation. Central toxic effects are characterized by agitation, anxiety, delirium, disorientation, hallucinations, hyperactivity, sedation, and seizures. Severe overdosage may produce coma, medullary paralysis, and death. Peripheral toxicity includes hypertension, tachycardia, dysrhythmias, vasodilation, hyperpyrexia, mydriasis, urinary retention, and diminished gastrointestinal motility. Dry mouth, pharynx, bronchi, and nasal passages may be observed.

Impaired secretion from sweat glands following toxic doses of drugs with anticholinergic side effects may predispose to hyperthermia.

An adult ingested 400 mg chlorpheniramine with no reported serious adverse effects. Toxic psychosis, a possible class effect from overdose of sedating antihistamines, has been reported with accidental overdose of chlorpheniramine.

Treatment of overdose consists of discontinuation of Vituz Oral Solution together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdose or unusual sensitivity to opioids including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.

Hemodialysis is not routinely used to enhance the elimination of chlorpheniramine from the body. Urinary excretion of chlorpheniramine is increased when the pH of the urine is acidic; however, acid diuresis is NOT recommended to enhance elimination in overdose, as the risks of acidemia and acute tubular necrosis in patients with rhabdomyolysis far outweigh any potential benefit.


11 DESCRIPTION

Vituz Oral Solution contains hydrocodone bitartrate (a semisynthetic centrally-acting opioid antitussive) and chlorpheniramine maleate (an antihistamine).

Each 5 mL dose of Vituz Oral Solution contains: hydrocodone bitartrate, USP, 5 mg and chlorpheniramine maleate, USP, 4 mg.


Vituz Oral Solution also contains: citric acid anhydrous, glycerin, grape flavor, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate, sodium saccharin, and sucrose.

Hydrocodone bitartrate is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5); also known as 4,5 α -Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine; and may be represented by the following structural formula:



Hydrocodone Bitartrate
 $C_{18}H_{21}NO_3 \cdot C_4H_6O_6 \cdot 2.5 H_2O$
 Molecular weight = 494.5

Chlorpheniramine maleate is 2-pyridinepropanamine, γ -(4-chlorophenyl)-*N,N*-dimethyl-, (*Z*)-2-butenedioate (1:1) and has the following chemical structure:



Chlorpheniramine Maleate
 $C_{16}H_{19}ClN_2 \cdot C_4H_4O_4$
 Molecular weight = 390.86

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the cough center. In excessive doses, hydrocodone will depress respiration. Hydrocodone can produce miosis, euphoria, and physical and physiological dependence.

Chlorpheniramine is an antihistamine drug (H₁ receptor antagonist) that also possesses anticholinergic and sedative activity. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa.

12.3 Pharmacokinetics

Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of hydrocodone bitartrate and chlorpheniramine maleate after single dose administration of 5 mL Vituz Oral Solution are equivalent to respective reference solutions of 5 mL hydrocodone bitartrate (5 mg/5 mL), and 5 mL chlorpheniramine maleate (4 mg/5 mL).

Hydrocodone had mean (SD) peak plasma concentration of 10.6 (2.63) ng/mL at 1.4 (0.55) hours. The mean plasma half-life of hydrocodone is approximately 4.9 hours. Chlorpheniramine had a mean (SD) plasma peak concentration of 7.20 (1.98) ng/mL at 3.5 (1.6) hours. The mean plasma half-life of chlorpheniramine is approximately 24 hours.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with Vituz Oral Solution; however, published information is available for the individual active ingredients or related active ingredients.

Hydrocodone:

Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 30 and 80 times, respectively, the MRHDD of hydrocodone on a mg/m² basis).

Chlorpheniramine:

In 2 year studies in F344/N rats and B6C3F1 mice, chlorpheniramine maleate showed no evidence of tumorigenicity when administered 5 days/week at oral doses up to 30 and 50 mg/kg/day, respectively (approximately 15 times the MRHDD on a mg/m² basis).

Chlorpheniramine maleate was not mutagenic in the in vitro bacterial reverse mutation assay or the in vitro mouse lymphoma forward mutation assay. Chlorpheniramine maleate was clastogenic in the in vitro CHO cell chromosomal aberration assay.

Chlorpheniramine maleate had no effects on fertility in rats and rabbits at oral doses approximately 20 and 25 times the MRHDD on a mg/m² basis, respectively.

14 CLINICAL STUDIES

Efficacy studies were not conducted with Vituz Oral Solution. Efficacy of Vituz Oral Solution is based on demonstration of bioequivalence to the individual reference products [*see Clinical Pharmacology (12.3)*].

16 HOW SUPPLIED/STORAGE AND HANDLING

Vituz Oral Solution is supplied as a clear, colorless to light yellow, grape-flavored solution containing 5 mg hydrocodone bitartrate and 4 mg chlorpheniramine maleate in each 5 mL. It is available in:

White HDPE bottles of one pint (480 mL): NDC 63717-877-16

Store solution at 20° to 25°C (68° to 77°F). [USP Controlled Room Temperature.]

Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.

17 PATIENT COUNSELING INFORMATION

17.1 Overdosage

Patients should be advised not to increase the dose or dosing frequency of Vituz Oral Solution because serious adverse events such as respiratory depression may occur with overdosage [*see Warnings and Precautions (5.1); Overdosage (10)*].

17.2 Dosing

Patients should be advised to measure Vituz Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose [*see Warnings and Precautions (5.8)*].

17.3 Concomitant Use of Alcohol and Other Central Nervous System Depressants

Patients should be advised to avoid the use of alcohol and other central nervous system depressants while taking Vituz Oral Solution because additional reduction in mental alertness may occur [*see Warnings and Precautions (5.4)*].

17.4 Activities Requiring Mental Alertness

Patients should be advised to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as Vituz Oral Solution may produce marked drowsiness [*see Warnings and Precautions (5.4)*].

17.5 Drug Dependence

Patients should be cautioned that Vituz Oral Solution contains hydrocodone bitartrate and can produce drug dependence [*see Warnings and Precautions (5.2)*].

17.6 MAOIs

Patients should be informed that they should not use Vituz Oral Solution with a MAOI or within 14 days of stopping use of an MAOI [*see Warnings and Precautions (5.7)*].

Manufactured for: Hawthorn Pharmaceuticals, Inc., Madison, MS 39110

Vituz[®] Oral Solution is a Registered Trademark of Hawthorn Pharmaceuticals, Inc.

Copyright © Hawthorn Pharmaceuticals, Inc.

HI279 02/13

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LYDIA I GILBERT MCCLAIN
02/20/2013